At Mablytics, our mission is to transform cancer care through precision.
Every year, over 10 million patients worldwide receive chemotherapy—a treatment approach that often harms healthy cells as much as it attacks cancer, leading to significant toxicity and reduced quality of life.
Studies show that systemic cancer therapies are associated with 2–7% early mortality rates, and among older or frail patients, serious toxicities occur in more than 50%, contributing to decline and treatment discontinuation.
We are changing that. By developing therapies guided by molecular insight and engineered for selectivity, we are building a new generation of immunotherapies that fight cancer with accuracy, spare healthy tissue, and give patients renewed hope for lasting recovery.